CeriBell, Inc. Stock Price, News & Analysis

Ceribell (NASDAQ: CBLL) reported strong Q1 2025 financial results with total revenue of $20.5 million, up 42% year-over-year. The company's performance was driven by expanded commercial adoption, with 558 total active accounts. Product revenue reached $15.6 million (41% increase) while subscription revenue hit $4.9 million (45% increase). Gross margin improved to 88%. Despite growth, net loss widened to $12.8 million due to increased operating expenses. Key achievements include FDA clearance for pediatric Clarity™ algorithm and becoming the first medical device company to receive FedRAMP High authorization. Ceribell raised its 2025 revenue guidance to $83-87 million, projecting 27-33% growth. The company maintains a strong financial position with $182.7 million in cash and equivalents.

Ceribell, a medical technology company specializing in neurological diagnostics, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Wednesday, May 14, 2025, at 10:55 AM PST (1:55 PM EST).

The presentation will be accessible to interested parties through a live webcast, which will also be archived for future reference. Viewers can access the webcast through the Investor Relations section of Ceribell's website at investors.ceribell.com.

Ceribell (Nasdaq: CBLL) focuses on transforming the diagnosis and management of serious neurological conditions through innovative medical technology solutions.

Ceribell has achieved FedRAMP High authorization for its AI-powered point-of-care EEG system, becoming one of only 51 companies in the U.S. to receive this elite cybersecurity designation. The company (Nasdaq: CBLL) can now expand its presence across federal healthcare facilities, including VA hospitals.

The authorization enables broader implementation of Ceribell's secure, cloud-based solution throughout federal healthcare agencies, facilitating faster diagnosis of non-convulsive seizures in veterans and high-risk patients. As of April 2025, fewer than 15% of FedRAMP Authorized systems meet the High security standard, and Ceribell is currently the only medical device company on the list.

The system, which received Authority to Operate (ATO) in 2024, is already in use at VA hospitals. This new authorization validates Ceribell's commitment to data security while enhancing patient care, positioning it among leading cloud and technology organizations meeting stringent federal cybersecurity standards.

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has scheduled its Q1 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results.

Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 7370458. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.

Ceribell (Nasdaq: CBLL) has received FDA 510(k) clearance for its Clarity™ algorithm, becoming the first and only AI-powered point-of-care EEG system cleared to detect electrographic seizures in patients aged 1 year and older. The clearance was supported by EEG data from over 1,700 patients, marking the largest validation dataset ever used for FDA clearance of a seizure detection system.

The Clarity algorithm works with Ceribell's existing EEG headbands and enables rapid, bedside detection, diagnosis, and treatment of non-convulsive seizures in children experiencing neurological emergencies. Clinical guidelines recommend initiating EEG within 15-60 minutes of suspected continuous non-convulsive seizures, but children often face hours or days of waiting for assessment. This technology aims to address this critical gap by providing immediate bedside neurological assessment.

Ceribell (NASDAQ: CBLL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $18.5 million, up 41% year-over-year, while full-year revenue grew 45% to $65.4 million. The company maintained robust gross margins of 88% in Q4 and 87% for the full year.

Key highlights include reaching 529 total active accounts and treating over 200,000 patients. However, operating expenses increased 49% to $29.1 million in Q4, resulting in a net loss of $12.6 million ($0.40 per share). Full-year net loss was $40.5 million ($3.39 per share).

The company ended 2024 with $194.4 million in cash and cash equivalents. Looking ahead, Ceribell projects 2025 revenue between $81-85 million, representing 24-30% growth. The company also submitted a 510(k) application for its pediatric Clarity™ algorithm to the FDA.

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., along with CFO Scott Blumberg, will engage in a fireside chat scheduled for March 3, 2025, at 6:50 AM PST / 9:50 AM EST.

Interested parties can access both live and archived versions of the presentation through the Investor Relations section of Ceribell's website at investors.ceribell.com.

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has announced its upcoming financial results release. The company will disclose its fourth quarter and full year 2024 financial results after market close on February 25, 2025.

Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 3782735. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jane Chao, Ph.D., CEO and Co-founder, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST.

The presentation will be accessible through a live and archived webcast in the Investor Relations section of Ceribell's website. The company focuses on revolutionizing the diagnosis and management of serious neurological conditions through innovative medical technology solutions.